| An unofficial legislative history of the Biologics Price Competition and Innovation Act 2009 KH Carver, J Elikan, E Lietzan Food & Drug LJ 65, 671, 2010 | 126 | 2010 |
| The surprising reach of FDA regulation of cannabis, even after descheduling SM O'connor Am. UL Rev. 68, 823, 2018 | 70 | 2018 |
| The Myths of Data Exclusivity E Lietzan LewIs & cLark L. rev. 20, 91, 2016 | 68 | 2016 |
| A brief history of 180-day exclusivity under the hatch-wasman amendments to the federal food, drug, and cosmetic act EK Lietzan Food & Drug LJ 59, 287, 2004 | 49 | 2004 |
| A new history and discussion of 180-day exclusivity DE Korn, E Lietzan, SW Scott Food & Drug LJ 64, 335, 2009 | 38 | 2009 |
| The Drug Innovation Paradox E Lietzan Mo. L. REv. 83, 39, 2018 | 37 | 2018 |
| The history and political economy of the Hatch-Waxman amendments E Lietzan Seton Hall L. Rev. 49, 53, 2018 | 36 | 2018 |
| Biosimilar monoclonal antibodies: the scientific basis for extrapolation H Schellekens, E Lietzan, F Faccin, J Venema Expert opinion on biological therapy 15 (11), 1633-1646, 2015 | 36 | 2015 |
| Paper promises for drug innovation E Lietzan Geo. Mason L. Rev. 26, 168, 2018 | 24 | 2018 |
| Outpatient civil commitment in North Carolina: Constitutional and policy concerns EF King Law and Contemporary Problems 58 (2), 251-281, 1995 | 23 | 1995 |
| Crippling the Innovation Economy: Regulatory Overreach at the Patent Office A Abbott, E Lietzan, A Mossoff, K Osenga, B O’Shaughnessy, HRR Rader, ... The US Patent System 5, 10, 2017 | 20 | 2017 |
| The law of 180–day exclusivity E Lietzan, J Post Food and Drug Law Journal 71 (3), 327-400, 2016 | 19 | 2016 |
| Issues in the Interpretation of 180-day Exclusivity E Lietzan, DE Korn Food and Drug Law Journal 62 (1), 49-75, 2007 | 19 | 2007 |
| Access before Evidence and the Price of the FDA's New Drug Authorities E Lietzan U. Rich. L. Rev. 53, 1243, 2018 | 17 | 2018 |
| The Uncharted Waters of Competition and Innovation in Biological Medicines E Lietzan Fla. St. UL Rev. 44, 883, 2016 | 15 | 2016 |
| A new framework for assessing clinical data transparency initiatives E Lietzan Marq. Intell. Prop. L. Rev. 18, 33, 2014 | 15 | 2014 |
| The" Evergreening" Metaphor in Intellectual Property Scholarship E Lietzan Akron L. Rev. 53, 805, 2019 | 14 | 2019 |
| Biosimilar naming: how do adverse event reporting data support the need for distinct nonproprietary names for biosimilars EF Lietzan, LE Sim, EA Alexander Food Drug Policy Forum 3 (6), 1-24, 2013 | 14 | 2013 |
| The Authority of a Court to Order Disgorgement for Violations of the Current Good Manufacturing Practices Requirement of the Federal Food, Drug, and Cosmetic Act E King, EM Walsh Food & Drug LJ 58, 149, 2003 | 10 | 2003 |
| The innovation paradox: pharmaceutical marketing exclusivity and incentives for drug development E Lietzan, KML Acri née Lybecker Journal of Pharmaceutical Health Services Research 10 (2), 169-175, 2019 | 9 | 2019 |
Patti ZettlerThe Ohio State University Moritz College of LawVerified email at osu.edu